Donald Dvorin, MD
Allergy & Immunology · Philadelphia, PANPI 1316095664
Payments from drug & device makers
Across 671 payments — averaging $14.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$2K
- Sanofi$650
- CSL Behring$543
- Kaleo, Inc.$437
- Novartis$426
- plus $4K from 27 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 117 | $2,430 |
| GSK | 152 | $1,606 |
| Sanofi | 47 | $650 |
| CSL Behring | 38 | $543 |
| Kaleo, Inc. | 30 | $437 |
| Novartis | 27 | $426 |
| Optinose US, Inc. | 30 | $361 |
| Biocryst US Sales Co., LLC | 26 | $323 |
| Alk-abello, Inc | 20 | $310 |
| Boehringer Ingelheim | 19 | $261 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $260 |
| Regeneron Healthcare Solutions, Inc. | 16 | $244 |
| Philips North America LLC | 15 | $243 |
| Mylan Specialty L.p. | 15 | $206 |
| Amgen | 13 | $188 |
| Bio Products Laboratory USA, Inc. | 11 | $186 |
| Grifols USA, LLC | 8 | $145 |
| Pharming Healthcare, Inc. | 10 | $145 |
| Pfizer | 8 | $123 |
| AbbVie | 10 | $117 |
| Covis Pharma GmbH | 6 | $96 |
| Genentech USA, Inc. | 5 | $87 |
| Aimmune Therapeutics, Inc. | 6 | $87 |
| Teva Pharmaceuticals USA, Inc. | 5 | $71 |
| Hikma Pharmaceuticals USA | 4 | $62 |
| Merck | 4 | $54 |
| Blueprint Medicines Corporation | 3 | $46 |
| Eyevance Pharmaceuticals LLC | 3 | $41 |
| Shire North American Group Inc | 3 | $40 |
| Electromed, Inc. | 1 | $15 |
| LEO Pharma Inc. | 1 | $15 |
| Octapharma USA, Inc. | 1 | $13 |
| Biocryst Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$9,844 in reported general payments places this provider in the 70th percentile of 175 allergy & immunology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other allergy & immunology in Philadelphia
- Drew WeissmanPhiladelphia$15.3M
- Rahul DattaPhiladelphia$198K
- Arnold LevinsonPhiladelphia$95K
- John BossoPhiladelphia$86K
- Elias AklPhiladelphia$80K
- Neha SirohiPhiladelphia$62K
- Marc GoldsteinPhiladelphia$22K
- Raquel EmpedradPhiladelphia$21K
- Karin Flynn-RoddenPhiladelphia$15K
- Irene HaralabatosPhiladelphia$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.